Full-Life Technologies

Full-Life Technologies Secures FDA IND Clearance for [²²⁵Ac]Ac‑FL‑261 – Potential First‑in‑Class c‑MET Alpha Radionuclide Conjugate Enters Phase I in Non‑Squamous NSCLC

Full-Life Technologies Limited announced that its Investigational New Drug (IND) application for Ac‑FL‑261 has been...

Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production

Fineline Cube May 19, 2026

Full-Life Technologies announced the successful completion of a $150 million financing round, comprising $110 million...

Company Deals

Full‑Life Technologies Raises $77 M in Series C and Debt Funding

Fineline Cube Sep 30, 2025

Full‑Life Technologies, a global radiotherapeutics integrator, announced today the successful completion of $77 million in financing,...

Company Deals

Full-Life Technologies Strikes USD 571.5 Million Licensing Deal with SK Biopharmaceuticals for Radiopharmaceutical Asset

Fineline Cube Jul 17, 2024

Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and...

Company Drug

Full-Life Technologies’ ²²⁵Ac-FL-020 Earns FDA Fast-Track Status for mCRPC

Fineline Cube Jul 4, 2024

Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and...

Company Drug

Full-Life Technologies Receives FDA Green Light for ²²⁵Ac-FL-020 Clinical Study in mCRPC

Fineline Cube May 30, 2024

Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and...

Company Deals

Full-Life Technologies Secures USD 63.3 Million in Financing to Boost Radiotherapeutics Pipeline and Manufacturing

Fineline Cube Jan 4, 2024

Full-Life Technologies Ltd, a global radiotherapeutics company with a presence in Belgium, Germany, and China,...

Company

Full-Life Technologies Ltd to Establish GMP-Compliant Radiopharmaceutical Plant in Belgium’s Wallonie Region

Fineline Cube May 4, 2023

Shanghai-headquartered Full-Life Technologies Ltd has announced a significant land acquisition deal in the Wallonie region...

Company Deals

Full-Life Technologies Acquires Focus-X Therapeutics to Expand Pipeline

Fineline Cube Nov 29, 2022

Shanghai-headquartered Full-Life Technologies Ltd has announced the acquisition of New Jersey-based Focus-X Therapeutics. The move...

Full-Life Technologies

Full-Life Technologies Secures FDA IND Clearance for [²²⁵Ac]Ac‑FL‑261 – Potential First‑in‑Class c‑MET Alpha Radionuclide Conjugate Enters Phase I in Non‑Squamous NSCLC

Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production

Full‑Life Technologies Raises $77 M in Series C and Debt Funding

Full-Life Technologies Strikes USD 571.5 Million Licensing Deal with SK Biopharmaceuticals for Radiopharmaceutical Asset

Full-Life Technologies’ ²²⁵Ac-FL-020 Earns FDA Fast-Track Status for mCRPC

Full-Life Technologies Receives FDA Green Light for ²²⁵Ac-FL-020 Clinical Study in mCRPC

Full-Life Technologies Secures USD 63.3 Million in Financing to Boost Radiotherapeutics Pipeline and Manufacturing

Full-Life Technologies Ltd to Establish GMP-Compliant Radiopharmaceutical Plant in Belgium’s Wallonie Region

Full-Life Technologies Acquires Focus-X Therapeutics to Expand Pipeline

You Missed

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories